Last reviewed · How we verify
NCT01833039
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
trial testing Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma. Approved for marketing.
Quick facts
| Lead sponsor | Janssen Biotech, Inc. |
|---|---|
| Status | APPROVED FOR MARKETING |
| Study type | EXPANDED_ACCESS |
| Sites | 51 locations across Puerto Rico, United States, Brazil |
Drugs / interventions tested
- Ibrutinib (ibrutinib) — full drug profile →
Conditions studied
- Relapsed or Refractory Mantle Cell Lymphoma — all drugs for Relapsed or Refractory Mantle Cell Lymphoma →
Sponsor
Janssen Biotech, Inc. — full company profile →
Who can join
18 and older, any sex, with Relapsed or Refractory Mantle Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01833039
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ibrutinib
Trials testing the same drug.
- NCT07377578 — A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel · Phase 3 · recruiting
- NCT07052695 — Mosunetuzumab for CLL MRD Clearance · Phase 1, PHASE2 · recruiting
- NCT06649812 — Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress · Phase 2 · recruiting
- NCT07169565 — Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia · Phase 1 · not yet recruiting
- NCT06357676 — Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial · Phase 1, PHASE2 · recruiting
Other Janssen Biotech, Inc. trials
Trials by the same sponsor.
- NCT02808780 — An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis · active not recruiting
- NCT01314118 — IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen · Phase 2 · completed
- NCT01081730 — Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database · completed
- NCT01081717 — Golimumab Safety and Surveillance Program Using the Ingenix NHI Database · completed
- NCT00606346 — A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01833039 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Biotech, Inc.
- Last refreshed: 3 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01833039.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing